Bruton's tyrosine kinase

Ibrutinib

Receptor

Leukemia

Coronavirus disease 2019 (COVID-19)

Immunology

Pulmonary Injury

Tyrosine kinase

Infectious disease (medical specialty)

Internal medicine

Pulmonary fibrosis

Medicine

Chronic lymphocytic leukemia

Disease

Lung

Blood

Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients